Pola Orbis Holdings Inc.
Latest From Pola Orbis Holdings Inc.
With Phase III data in 2,800 patients for reducing frown lines, ReVance anticipates filing RT002 for US approval in 2019. ABL licenses two bispecific antibody candidates to TRIGR, while Sun looks to expand in dermatology with Pola buyout.
The NPD Group reports a 4% decline in U.S. beauty shoppers in 2014; Avon releases its fiscal 2014 results, while Energizer announces its personal-care spinoff will be called Edgewell Personal Care. More news in brief.
Ranbaxy Laboratories has launched the antifungal luliconazole (marketed as Lulifin) in India. The product is licensed from Japan's Summit Pharmaceuticals International Corporation (SPI).
Pola Pharma is to begin co-promoting four GlaxoSmithKline topical products in Japan from July 1st, in a tie-up aimed at strengthening the UK group's presence in this sector.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.